| Drug Name |
Halobetasol propionate |
| Drug ID |
BADD_D01052 |
| Description |
Ulobetasol is a highly potent corticosteroid.[A215597] It is structurally related to [clobetasol].[A215597] Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.[L15047,L15052,L15102]
Ulobetasol was granted FDA approval on 17 December 1990.[L15047] |
| Indications and Usage |
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
D07AC21 |
| DrugBank ID |
DB00596
|
| KEGG ID |
D04409
|
| MeSH ID |
C064466
|
| PubChem ID |
48175
|
| TTD Drug ID |
D00XPC
|
| NDC Product Code |
0713-0758; 64918-1206; 51862-606; 52128-138; 45802-129; 63629-8735; 0713-0339; 70752-119; 51672-1321; 51862-604; 10631-122; 45802-131; 58175-0391; 0713-0640; 0187-0002; 52565-073; 63629-8665; 22552-0001; 63739-998; 0168-0355; 50909-5157; 46204-0188; 63629-8664; 51672-1322 |
| Synonyms |
halobetasol | ulobetasol | Ultravate | halobetasol propionate | 6 alpha-fluoroclobetasol 17-propionate | 6-fluoroclobetasol 17-propionate | CGP 14 458 | CGP-14458 | CGP 14458 |
